Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRQR Stock Forecast 2026-2027
$1.53
Current Price
$161.20M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PRQR Price Targets
+815.0%
To High Target of $14.00
+455.6%
To Median Target of $8.50
+161.4%
To Low Target of $4.00
PRQR Price Momentum
+4.1%
1 Week Change
-3.2%
1 Month Change
-16.4%
1 Year Change
-24.3%
Year-to-Date Change
-50.6%
From 52W High of $3.10
+15.0%
From 52W Low of $1.33
📊 TOP ANALYST CALLS
Did PRQR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ProQR is one of their latest high-conviction picks.
Latest PRQR Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PRQR has a bullish consensus with a median price target of $8.50 (ranging from $4.00 to $14.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $1.53, the median forecast implies a 455.6% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Keay Nakae at Chardan Capital, suggesting a 161.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRQR Analyst Ratings
8
Buy
0
Hold
0
Sell
PRQR Price Target Range
Low
$4.00
Average
$8.50
High
$14.00
Current: $1.53
Latest PRQR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRQR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 9, 2026 | Chardan Capital | Keay Nakae | Buy | Maintains | $4.00 |
| Nov 4, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 8, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jun 27, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Jun 27, 2025 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| May 13, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Apr 29, 2025 | Evercore ISI Group | Outperform | Initiates | $N/A | |
| Mar 14, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 14, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 12, 2025 | Jones Trading | Buy | Initiates | $N/A | |
| Dec 12, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Dec 12, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 29, 2024 | Raymond James | Strong Buy | Upgrade | $N/A | |
| May 10, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| May 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 18, 2024 | Citigroup | Neutral | Maintains | $N/A | |
| Mar 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 14, 2024 | HC Wainwright& Co. | Buy | Reiterates | $N/A |
ProQR Therapeutics N.V. (PRQR) Competitors
The following stocks are similar to ProQR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ProQR Therapeutics N.V. (PRQR) Financial Data
ProQR Therapeutics N.V. has a market capitalization of $161.20M with a P/E ratio of -3.9x. The company generates $15.72M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -57.1% quarter-over-quarter, while maintaining an operating margin of -671.4% and return on equity of -78.1%.
Valuation Metrics
Market Cap
$161.20M
Enterprise Value
$106.82M
P/E Ratio
-3.9x
PEG Ratio
-0.1x
Price/Sales
11.6x
Growth & Margins
Revenue Growth (YoY)
-57.1%
Gross Margin
N/A
Operating Margin
-671.4%
Net Margin
0.0%
EPS Growth
-55.0%
Financial Health
Cash/Price Ratio
+50.3%
Current Ratio
2.5x
Debt/Equity
41.8x
ROE
-78.1%
ROA
-23.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ProQR Therapeutics N.V. (PRQR) Business Model
About ProQR Therapeutics N.V.
What They Do
Develops RNA-based therapies for genetic disorders.
Business Model
ProQR Therapeutics generates revenue by developing and commercializing innovative RNA-based therapies targeting genetic disorders. The company focuses on rare genetic diseases, particularly genetic eye diseases, leveraging advanced RNA-editing technologies to create effective treatments where few alternatives exist. Its commitment to research and development positions it to potentially partner with larger pharmaceutical companies for distribution and funding.
Additional Information
Founded in 2012 and based in the Netherlands, ProQR is recognized for its pioneering role in genetic research and innovation. The company is actively involved in advancing the field of RNA therapy, with a pipeline of therapies designed to address significant unmet medical needs, impacting both patients and the broader healthcare industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
166
CEO
Mr. Daniel Anton de Boer
Country
Netherlands
IPO Year
2014
Website
www.proqr.comProQR Therapeutics N.V. (PRQR) Latest News & Analysis
Latest News
Quick Summary
ProQR Therapeutics targets Q2 2026 for AX-0810 data in healthy volunteers, with biliary atresia as a Phase 2 focus. They ended Q1 2026 with €81.1M cash, funding operations into mid-2027.
Why It Matters
ProQR's clinical advancements and strong cash position suggest potential growth and reduced financial risk, making it an attractive option for investors seeking biotech opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR Therapeutics N.V. announced news from Leiden, Netherlands, and Cambridge, Mass. on May 11, 2026. Further details were not provided in the excerpt.
Why It Matters
ProQR Therapeutics' announcement may signal developments in biotech that could affect stock prices, investor sentiment, and market trends in gene therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR (PRQR) is not expected to meet the criteria for a potential earnings beat in its upcoming earnings report. Investors should be aware of this outlook.
Why It Matters
ProQR's lack of key ingredients for an earnings beat signals potential underperformance, which could negatively impact stock prices and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
ProQR Therapeutics N.V. announced developments from Leiden, Netherlands, and Cambridge, Mass. on May 4, 2026. Further details were not provided in the excerpt.
Why It Matters
ProQR Therapeutics' announcement may signal developments in biotechnology that could influence stock performance, impact market trends, and affect investor sentiment in the sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR Therapeutics has nominated Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors, enhancing its leadership in RNA therapies.
Why It Matters
The nomination of a seasoned executive from a major pharmaceutical company to ProQR's Board could enhance credibility, strategic direction, and potential partnerships, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR Therapeutics N.V. (PRQR) held a shareholder/analyst call, discussing company updates and future prospects. For detailed insights, refer to the transcript.
Why It Matters
The ProQR Therapeutics shareholder call may provide insights into financial performance, future guidance, and strategic plans, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About PRQR Stock
What is ProQR Therapeutics N.V.'s (PRQR) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, ProQR Therapeutics N.V. (PRQR) has a median price target of $8.50. The highest price target is $14.00 and the lowest is $4.00.
Is PRQR stock a good investment in 2026?
According to current analyst ratings, PRQR has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRQR stock?
Wall Street analysts predict PRQR stock could reach $8.50 in the next 12 months. This represents a 455.6% increase from the current price of $1.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ProQR Therapeutics N.V.'s business model?
ProQR Therapeutics generates revenue by developing and commercializing innovative RNA-based therapies targeting genetic disorders. The company focuses on rare genetic diseases, particularly genetic eye diseases, leveraging advanced RNA-editing technologies to create effective treatments where few alternatives exist. Its commitment to research and development positions it to potentially partner with larger pharmaceutical companies for distribution and funding.
What is the highest forecasted price for PRQR ProQR Therapeutics N.V.?
The highest price target for PRQR is $14.00 from at , which represents a 815.0% increase from the current price of $1.53.
What is the lowest forecasted price for PRQR ProQR Therapeutics N.V.?
The lowest price target for PRQR is $4.00 from Keay Nakae at Chardan Capital, which represents a 161.4% increase from the current price of $1.53.
What is the overall PRQR consensus from analysts for ProQR Therapeutics N.V.?
The overall analyst consensus for PRQR is bullish. Out of 2 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.50.
How accurate are PRQR stock price projections?
Stock price projections, including those for ProQR Therapeutics N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 5:12 AM UTC